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ABSTRACT  
Objective: The aim of the present study was to formulate and evaluate the Solid Lipid Nanoparticles (SLNs) of Ropinirole Hydrochloride (ROP). 
Methods: ROP-loaded SLNs were prepared by a double emulsion method using glyceryl monostearate (GMS) as lipid and soya lecithin as a 
stabilizer. All formulated ROP-loaded SLNs were characterized for its particle size and size distribution, zeta potential, % Entrapment Efficiency 
(EE) and drug loading. The formulations were optimized in terms of GMS to soya lecithin ratio and sonication time of primary emulsion. Shape and 
surface morphology of the optimized formulation was studied using optical microscopy and scanning electron microscopy. In vitro and ex vivo Study 
of optimized formulation was also performed and compared with a pure drug solution.  
Results: The particle size and polydispersity index (PDI), zeta potential and EE of optimized formulation were found to be 320±5.15 nm, 
0.260±0.012,-37.9±1.43, 56.13±2.33% respectively. In vitro and ex vivo permeation study revealed that percentage cumulative drug release of 
optimized formulation was found to be 58.45±1.75% and 53.75±1.34 % respectively in 24 h and more than 90% drug release from pure drug 
solution was found to be within 6 h. Drug release from the formulation is sustained as compared to the plain drug solution which release 97.74 % 
(in vitro) and 88.15 % (ex vivo) of the drug within 6 h. 
Conclusion: From the results, it concludes that drug released from SLNs follows sustained release pattern and it will enhance the overall activity of 
the drug.  
Keywords: Ropinirole hydrochloride, Solid lipid nanoparticles, Double emulsion method. 
 
INTRODUCTION 
Parkinson's Disease (PD) is a degenerative disorder of the central 
nervous system. It occurs due to the death of dopamine-generating 
cells in the substantia nigra, a region of the midbrain; the cause of 
this cell death is unknown. PD is characterized typically by motor 
features of tremor, rigidity, bradykinesia and postural instability and 
non-motor disorder symptoms such as Dementia, Depression, and 
falls or emerges with the progression of the disease [1]. Ropinirole 
Hydrochloride (ROP) has been a recently introduced selective non-
ergoline dopamine D2 receptor agonist, which stimulates striatal 
dopamine receptors to produce dopamine, for the treatment of PD.  
ROP is a low molecular weight, highly water soluble drug. It is 
rapidly absorbed from the gastrointestinal tract and mean peak 
plasma concentrations have been achieved within 1.5 h after oral 
doses. The oral bioavailability of ROP is 50% due to extensive first 
pass metabolism by the liver. Its mean plasma half-life is 5–6 h [2, 3]. 
The starting dose of ROP is 2 mg taken once daily for 1 to 2 weeks, 
followed by increases of 2 mg/d for one week and so on. For that, 
the patient has to take a conventional IR tablet 3-4 times a day [4]. 
The drawback of conventional dosages can be overcome by 
formulating sustained release Solid Lipid Nanoparticles (SLNs) of 
ROP. Sustained drug release reduces the dosing frequency, 
minimizing the side effect, enhanced therapeutic efficacy and 
prevention of hepatic first pass metabolism of the drug and 
improves the bioavailability of drugs. The treatment of all 
neurodegenerative diseases is a big challenge because of the 
numerous protective barriers surrounding the central nervous 
system. Pharmaceutical agents that are used to treat 
neurodegenerative diseases are usually administered orally, such as 
donepezil, memantine, rivastigmine etc., However, most of the 
ingested drugs do not reach the brain entirely because some of them 
are not able to cross the blood brain barrier (BBB) in adequate 
quantity and are, instead, metabolized totally or partially by the 
liver. This inefficient utilization of drugs may require ingestions of 
higher drug concentrations that can produce toxic effects in the 
heart, liver, or kidney [5]. The targeting of drug to the Central 
Nervous System (CNS), for the therapeutic advancement of 
neurodegenerative disorders such as Alzheimer’s, Parkinson’s 
disease, etc. can be done by administering the drug formulation like 
polymer nanoparticle [6], SLNs [7], liposome [8] etc., which can 
cross the BBB [9] or by administering the drug formulation through 
intranasal route which can bypass the BBB [10, 11].  
SLNs are the rapidly developing field of nanotechnology with several 
potential applications in drug delivery and research. Due to their 
unique size dependent properties, lipid nanoparticles offer the 
possibility to develop new therapeutics. The ability to incorporate 
drugs into nanocarriers offers a new prototype in drug delivery that 
could use for drug targeting. Hence SLNs hold great promise for 
reaching the goal of controlled and site specific drug delivery and 
hence attracted wide attention of researchers [12, 13]. Hence the 
present study was aimed to formulate the SLNs of ROP, to overcome 
the drawbacks of the conventional tablet dosage form and also ensure 
the sustained release profile of the drug from dosages from. 
MATERIALS AND METHODS 
Materials 
Ropinirole Hydrochloride (ROP) was received as a generous gift 
from Orchid Pharmaceuticals Pvt. Ltd., (Chennai, India). Glycerol 
monostearate (GMS), Soya lecithin and tween 80 (sorbitate 
monooleate) were procured from Sigma Aldrich Chemicals Pvt. Ltd., 
USA. Chloroform was obtained from Loba chemie Pvt. Ltd. (Mumbai, 
India). Dialysis membrane procured from Hi media Laboratories Pvt. 
Ltd., (Mumbai, India). All other chemicals used were of analytical 
grade and procured from S. D. Fine Chemicals (Mumbai, India). 
Methods 
Preparation of ROP loaded SLNs (ROP-SLNs) 
ROP-loaded SLNs were prepared using double emulsion methods 
[14] which were earlier reported for encapsulation of hydrophilic 
drugs, with slight modifications as per our laboratory setup. 
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Preparation of primary emulsion (W/O emulsion)  
1 ml of aqueous ROP solution containing 2% (w/v) Tween 80 was 
added drop wise into 10 ml of hot chloroform (50 °C) containing 
different ratios of GMS: Soya lecithin with continuous stirring at 500 
rpm using a magnetic stirrer followed by Probe sonication at an 
amplitude of 50, pulse 5 sec on and 3 sec off for 5 min. The 
temperature was maintained at 50 °C throughout this experiment 
(table 1). 
Preparation of double emulsion (W/O/W emulsion) 
The primary W/O emulsion from the previous step was added drop 
wise to 50 ml of hot aqueous phase (50 °C) containing stabilizer (2% 
(w/v) Tween 80) with continuous stirring at 1,000 rpm. This 
mixture was then probed sonicated at amplitude of 50, pulse 5 sec 
on and 3 sec off for 10 min. The resultant W/O/W double emulsion 
was further added to 50 ml of cold water (2–4 °C) for solidification 
of lipid nanoparticles. Chloroform was removed from keeping the 
formulation on a magnetic stirrer for few hrs. The nanoparticles 
dispersion was then centrifuged at 35,000×g for 30 min and washed 
twice with purified water. 
Optimization of process variables 
The W/O/W double emulsion was optimized in terms of GMS to soya 
lecithin ratio and droplet size reduction method by sonication. A 5 % 
(w/w) theoretical loading of drug with respect to the GMS was taken 
as a constant parameter unless specified.  
For optimization of GMS to soya lecithin ratio, SLNs with different 
lipid ratios (90:10, 85:15, 80:20, and 75:25 (w/w)) were prepared 
(keeping other parameters constant) and their effect of particle size 
and entrapment efficiency was studied (table 2) [14]. 
 
Table 1: Composition of ROP loaded SLNs 
Formulation code Drug loaded (%) GMS/Soya lecithin ratio (W/W)  Tween 80 (%w/v) 
F1 5 90:10 2 
F2 5 85:15 2 
F3 5 80:20 2 
F4 5 75:25 2 
 
For optimization of GMS to soya lecithin ratio, the primary emulsion 
was prepared by sonication at 50 Hz amplitude for 5 min while 
double emulsion was by sonication at 50 Hz amplitude for 10 min. 
However, these standard conditions resulted in relatively large 
particles, which necessitated further optimization of droplet size 
reduction by modifying the sonication time (2.5, 5.0, 10, and 12.5 
min with other parameters maintained constant) (table 3) for 
primary emulsion.  
Characterization of ROP-SLNs 
Particle size and size distribution and Zeta potential 
The particle size, PDI and Zeta potential of SLNs was determined by 
using Zeta Sizer by dynamic light scattering (Nano ZS, Malvern 
Instruments, UK). Six replicates were measured and values were 
measured as mean±standard deviation (SD). The zeta potential of a 
particle is the overall charge that the particle acquires in a particular 
medium. Knowledge of the zeta potential of SLNs helps to assess the 
stability of the formulation during storage [14, 15].  
Optical photo microscopy 
Colloidal dispersion of SLNs was placed on a clean glass slide and 
viewed by MOTIC digital photographic microscope under 45X 
magnification. Size (μ) of the MLVs was also measured using the 
microscopic scale. 
Scanning electron microscopy (SEM) 
Shape and surface morphology of the SLNs were studied using SEM 
(JEOL, JSM 50A, Tokyo, Japan). An appropriate amount of colloidal 
dispersion of SLNs was mounted onto metal (aluminium) using 
double-sided adhesive tape and fractured with a razor blade. The 
samples were sputter-coated with gold/palladium for 120 sec at 14 
mA under argon atmosphere for secondary electron emissive SEM and 
observed for morphology, at an acceleration voltage of 15 KV [14]. 
Entrapment efficiency (EE) and drug loading  
For determining the EE, SLNs dispersion was centrifuged at 20000 
rpm for 30 min using a cold centrifuge at 4 °C. The clear 
supernatant was decanted. Pellets of ROP-SLNs were washed with 
water and recent rifuged to remove an un entrapped drug. The 
two supernatant were combined and after suitable dilution the 
absorbance was recorded at 250 nm by keeping blank as drug free 
SLNs [13, 15]. 
 
 
In vitro drug release  
An in vitro drug release from ROP-SLNs formulation was performed 
using Franz diffusion cell across the dialysis membrane (12 Kda, Hi 
Mediam). The membrane was soaked in deionized water for 12 h 
before use. The donor compartment containing 1 ml of ROP-SLNs 
and the receptor compartment was filled with 80 ml of phosphate 
buffer solution (pH 6.4), within the pH range in the nasal cavity, as 
the dissolution medium (n=6).  
The dissolution medium was maintained at 37±0.5 ºC using 
circulating water bath and the medium was stirred at 200 rpm with 
the help of small teflon coated magnetic bead. The beaker was kept 
covered throughout the study to preclude evaporation of the 
medium. Aliquots of the medium were withdrawn at suitable time 
intervals and were replaced with the same volume of fresh medium 
to maintain the sink condition. These samples were assayed using 
UV-Vis spectrophotometer (1700, Shimadzu®
Ex vivo drug release 
, Tokyo, Japan) at a 
wavelength of 250 nm [13]. 
Ex vivo drug permeation studies were performed using Franz 
diffusion cell across the sheep nasal mucosa as the permeation 
barrier, obtained from a local slaughterhouse within 1 h of 
sacrificing the animal. Nasal mucosa was carefully cut with a 
scalpel and mounted on the diffusion chamber with mucosal and 
serosal surfaces facing donor and receptor compartments, 
respectively. Other experimental and sample collection 
procedures were performed in same fashion as in vitro diffusion 
studies [13].  
Drug release kinetics 
To study drug release kinetics of SLNs formulation, data 
obtained from in vitro and ex vivo drug release studies were 
plotted in various kinetic models: zero order (see Equation: 1) as 
cumulative percentage of drug released versus time, first order 
(see Equation: 2) as log cumulative percentage of drug 
remaining versus time [16]. 
Zero order equation Qt = Ko
First order equation In Q
t (1) 
t = In Q0+K1
Where Q
t (2) 
t is the percentage of drug release at time t and K0 and Kt 
are the coefficients of the equation. 
Priya et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 9, 85-89 
87 
Mechanism of drug release 
Mechanism of drug release from drug-loaded SLN was evaluated by 
subjecting the data obtained from in vitro drug diffusion studies in 
Higuchi’s model (see Equation: 3) as cumulative percentage of drug 
released versus square root of time and Korsmeyer–Peppa’s model (see 
equation: 4) as log cumulative percentage drug released versus log time.  
Higuchi equation Qt = Kt1/2(3) 
Korsmeyer and peppas equation Qt= Kp tn(4) 
Kp is constantly incorporating structural and geometrical 
characteristics of the release device and n is the release exponent 
indicate the release mechanism [16].  
Drug excipient compatibility studies by using fourier transform 
infrared spectroscopy  
IR spectroscopy was studied using a Shimadzu FTIR 8300 
Spectrophotometer and the spectrum was recorded in the region of 
2000 to 400 cm-1
ROP-SLNs were formulated by using different ratios of GMS and 
Soya lecithin. The particle size and EE of different formulation was 
shown in table 2. The particle size and PDI of SLNs decreased as the 
GMS: Soya lecithin ratio was decreased in the final dispersion. 
Highest drug entrapment was found at 80:20 (w/w; GMS/soya 
lecithin) ratio and, therefore, used for optimization of sonication 
time. In table 3 showed the effect of droplet size reduction method 
on the particle characteristics of SLNs. As sonication time increased 
(from 2.5 to 10.0 min) led to a significant decreased in the particle 
size (534±6.75 to 320±5.15) and PDI (0.553±0.016 to 0.260±0.012) 
of the resultant emulsion droplets. Further increase in sonication 
time from 10 to 12.5 min was accompanied by increased droplet 
size. Hence, a sonication time of 10 min was taken as optimum for 
the preparation of primary W/O emulsions. 
. The procedure consisted of dispersing a sample 
(table 1) in KBr (200-400 mg) and compressing into the discs by 
applying a pressure of 5 tons for 5 min in a hydraulic press. The pellet 
was placed in the light path and the spectrum was obtained [15]. 
RESULTS AND DISCUSSION  
Preparation and optimization of ROP-SLN 
Characterization of SLNs 
Particle size, PDI, zeta potential and EE 
The mean±SD particle size, PDI and zeta potential and EE of the all 
formulations are given in table 2. Optimization of sonication time for 
primary W/O emulsion for F3 formulation based on particle size, 
PDI and Zeta potential are given in table 3. Not much change was 
found in % EE (56 to 57 %) after altering the sonication time for 
primary W/O emulsion. Based on particle size and % EE, 80:20 
(W/W) ratio of GMS/Soya lecithin was selected as optimized ratio 
for SLNs formulation (F3 formulation) and primary emulsion 
sonication time was selected as 10 min based on particle size (F3b 
Shape and morphology 
Formulation). 
From optical photomicrography, it was clear that ROP-SLNs formed 
were spherical in shape and uniform in size. The SEM study reveals 
that SLNs were spherical in shape with an average particle size 
around 320±5.15 nm (n=200). Optical and SEM image of SLNs is 
shown in fig. 3a & 3b
 
. Occasional clumps observed in the images 
might be due association occur with the shrinkage of SLNs during 
drying or concentration of dispersion medium. 
Table 2: Effect of GMS: soya lecithin ratio on particle size, PDI, zeta potential and EE 
Formulation 
code 




PDI Zeta potential 
(mV) 
EE (%) Drug loading 
(%) 
F1 90:10 867±6.75 0.753±0.016 -36.4±2.32 29.33±2.32 1.45 
F2 85:15 571.6±6.27 0.685±0.005 -33.0±1.24 43.29±1.67 2.17 
F3 80:20 462.2±4.55 0.547±0.013 -31.6±1.13 56.13±2.13 2.81 
F4 75:25 433.1±5.95 0.288±0.006 -36.7±1.42 36.12±1.98 1.82 
 
Table 3: Optimization of sonication time for primary W/O emulsion for F3 based on particle size, PDI and zeta Potential 
Formulation no Sonication time (min) Particle Size (nm) PDI Zeta potential (mV) 
F3 2.5 a 534±6.75 0.553±0.016 -35.4±1.32 
F3 5 462.2±4.55 0.495±0.005 -31.6±1.113 
F3 10 b 320±5.15 0.260±0.012 -37.9±1.43 
F3 12.5 c 357.1±6.95 0.388±0.006 -36.76±2.11 
 
 




Fig. 2: Graph showing the zeta potential of optimized 
formulation (F3b) 
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Fig. 3A: Optical micrographs 3B: SEM image of optimized formulation of ROP-SLNs 
 
In vitro and ex vivo drug release studies  
In vitro and ex vivo release of ROP from SLNs formulation and pure 
drug solution are illustrated in fig. 4a & 4b. The release curve of 
ROP-SLNs exhibited a biphasic pattern in both in vitro and ex vivo 
release. There was an initial burst drug release through in vitro was 
39.13% and ex vivo was 30.45 % within the initial 6 h, followed by a 
slow and sustained release. 
 
 
Fig. 4a: In vitro release profile of optimized formulation and 
pure drug solution 
 
 
Fig. 4b: Ex vivo release profile of optimized formulation and 
pure drug solution 
 
The amount of cumulated drug release over 24 h through in vitro 
was 58.51% and ex vivo was 53.75 %. The in vitro and ex vivo drug 
release from the pure drug solution were found to be 97.74 % and 
88.15 %, respectively within 6 h and reached 99.38 % and 93.66 % 
by 24 h. 
Kinetic parameter for in vitro and ex vivo drug release from pure 
drug solution and optimized formulation (F3b
 
) were given in table 4 
Table 4: Kinetic parameter for in vitro and ex vivo drug release from pure drug solution and optimized formulation (F3b
Kinetic m. odel 
) 
In vitro release Ex vivo release 
Pure drug solution Optimized formulation (F5) Pure drug solution Optimized formulation (F5) 
Zero Order y = 3.164x+39.47 
R² = 0.462  
y = 2.117x+12.63 
R² = 0.790  
y = 2.651x+41.49 
R² = 0.494  
y = 1.794x+11.06 
R² = 0.887  
First Order y =-0.075x+1.655 
R² = 0.728  
y =-0.014x+1.943 
R² = 0.875  
y =-0.043x+1.737 
R² = 0.747  
y =-0.011x+1.952 
R² = 0.940  
Higuchi y = 18.19x+28.46 
R² = 0.701  
y = 12.88x+0.177 
R² = 0.934  
y = 17.92x+22.59 
R² = 0.721  
y = 10.66x+1.264 
R² = 0.975  
Korsmeyer Peppas model y = 0.410x+1.593 
R² = 0.854  
 
y = 0.602x+1.040 
R² = 0.962  
n= 0.602 
y = 0.475x+1.505 
R² = 0.836  
 
y = 0.494x+1.053 
R² = 0.987  
n=0.494 
 
Table 5: Major IR peak of pure ROP and Optimized Formulation of ROP-SLNs 
Samples  Composition  Major peak (wave numbers. cm-1) 
A Pure ROP 3415.93, 2968.45, 2881.65, 1729.36, 1703.14, 1614.42, 1382.96, 1242.94, 1051.20, 557.42 
B Optimized formulation of ROP-SLNs 3415.93, 291813, 2850.76, 1712.79, 1641.41, 1359.82, 1222.87, 1093.64, 536.21 
 
Drug excipients compatibility studies (FTIR) 
No considerable changes in the IR peaks of the drug were observed 
in the optimized formulation when compared with the pure drug, 
which indicate the absence of any chemical incompatibility between 
drug and excipients. 
DISCUSSION 
Formulation optimization 
For the preparation of ROP loaded SLNs, in the present study, double 
emulsion method has been chosen since it is a very well known 
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technique for the encapsulation of hydrophilic molecules in SLNs 
[14]. GMS was used as the solid lipid and soya lecithin as a stabilizer. 
Amphiphilic soya lecithin has the ability to modify the lipid matrix 
and results in enhanced drug loading capacity of SLNs [17]. As 
shown in table 2, a decrease in GMS/soya lecithin ratio from 95:5 to 
80:20 (w/w) led to a significant reduction in particle size. As the 
concentration of soya lecithin increased, particle size and PDI of SLN 
decreased considerably. This might be recognized to be the 
amphiphilic nature of the soya lecithin, which facilitated its 
adsorption onto the surface of emulsion droplets and aided in the 
reduction of droplet size [18]  
In present study sonication was employed as a tool for reducing 
droplet size of primary W/O emulsion preparation because the 
volume of primary emotion is less (1 ml). From table 3, it is 
observed that an increase in sonication time led to a significant 
decrease in droplet size. However, this phenomenon was observed 
up to 10 min because higher sonication led to excessive input of 
energy and shear during the emulsion formation which might have 
caused the formation of non-uniform layer of stabilizer, and hence 
led to increase particle size of SLNs [14]. Zeta potential of all 
formulations was more than±30 mV, therefore particles are 
normally considered as stable [19]. PDI is an indicator of 
homogeneity of the size distribution. Lower the PDI higher will be 
homogeneity of the size distribution. PDI of optimized formulation 
was found to be 0.260±0.012, conclude that particle was uniform in 
size and it was uniformly distributed [20]. As the ratio of GMS/Soya 
lecithin decreases entrapment efficiency increases, because as the 
concentration of soya lecithin was increases the film forming 
capacity of it was increased and the result of that % EE was 
increased (see in table 2). 
In vitro and ex vivo release studies and kinetics model 
The release pattern of drug revealed a biphasic pattern in both in 
vitro and ex vivo curve. They initially showed bust release, which 
may be due to retention of small unentrapped free drug on the 
surface of SLNs [15], followed by sustained release, which may be 
due to loading and deposition of the drug inside the cavities of GSM 
and results in low diffusion of drug molecules through the lipid 
matrix of the nano particles [13]. Sustain release of drug contributes 
to maintaining the effective therapeutic drug concentrations. Ex vivo 
% drug release is less when compared to in vitro, because some 
amount of drug is retained in mucosal layer.  
Released data were fitted to kinetic models in order to investigate 
the drug release kinetics. It was found that, in vitro and ex vivo drug 
release was best fitted to First order as the plot showed highest 
linearity regression coefficient (R2) of 0.875 and 0.940 respectively 
compared to zero order kinetic model. Release data were also fitted 
to Korsmeyer Peppa’s exponential model to investigate the 
mechanism of drug release from SLNs. The corresponding in vitro 
and ex vivo drug release plot of Korsmeyer–Peppa’s equation 
indicated a good linearity of regression coefficients (R2
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) 0.962 and 
0.987 respectively. Release exponent (n) was found to be 0.602 (in 
vitro) and 0.492 (ex vivo) respectively which is more above 0.45, so 
that the release can be characterized by Non–Fickian (anomalous) 
diffusion, which may indicate that the drug release rate is controlled 
by more than one mechanism i.e. Diffusion coupled with erosion 
mechanism for and drug release [16] 
CONCLUSION 
SLNs of ROP (a hydrophilic drug) were prepared by an optimized 
double emulsion process using GMS as solid lipid and soya lecithin 
as the stabilizer. Desired particle size of SLNs was obtained by 
increasing soya lecithin concentration as well as increasing 
sonication time of primary emulsion. The ROP-SLN obtained in vitro 
and ex vivo release experiments, exhibited a biphasic release pattern 
with burst release at the initial phase followed by sustained release 
compared to pure drug solution. However, in vivo studies for ROP-
SLN should be performed to determine its brain delivery efficacy. 
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